SPONSOR
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Total Trials
2
Recruiting
2
Phases
Phase 1, Phase 2, Phase 2
Suzhou Zelgen Biopharmaceuticals Co.,Ltd is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Neuroendocrine Carcinoma, Hepatocellular Carcinoma.
The trial portfolio spans Phase 1, Phase 2, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Suzhou Zelgen Biopharmaceuticals Co.,Ltd
How many clinical trials has Suzhou Zelgen Biopharmaceuticals Co.,Ltd sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, of which 2 are actively recruiting participants. These trials cover conditions including Neuroendocrine Carcinoma, Hepatocellular Carcinoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Suzhou Zelgen Biopharmaceuticals Co.,Ltd research focus on?
Suzhou Zelgen Biopharmaceuticals Co.,Ltd clinical trials span Neuroendocrine Carcinoma, Hepatocellular Carcinoma. The research pipeline includes Phase 1, Phase 2, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Suzhou Zelgen Biopharmaceuticals Co.,Ltd clinical trial?
To participate in a Suzhou Zelgen Biopharmaceuticals Co.,Ltd trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Suzhou Zelgen Biopharmaceuticals Co.,Ltd trials with current recruitment status updated daily.
Clinical Trials by Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT06440057 Phase 1, Phase 2
Recruiting
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.
Neuroendocrine Carcinoma
NCT06558227 Phase 2
Recruiting
Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology